Top

Cancer Causes & Control

Published in:

01-07-2015 | Original paper

Use of nonsteroidal anti-inflammatory drugs and risk of endometrial cancer: a nationwide case–control study

Authors: Nanna Brøns, Louise Baandrup, Christian Dehlendorff, Susanne K. Kjaer

Published in: Cancer Causes & Control | Issue 7/2015

Abstract

Purpose

We examined the association between use of low-dose aspirin and non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) and endometrial cancer risk in a nationwide case–control study.

Methods

Cases were all women in Denmark diagnosed with endometrial cancer during 2000–2009. Age-matched female controls were randomly selected by risk-set sampling. Information on NSAID use was collected from the Prescription Registry and classified according to duration and intensity. Conditional logistic regression was used to calculate odds ratios (ORs) and 95 % confidence intervals (CIs), adjusting for potential confounders. Analyses were stratified by endometrial cancer type, and potential effect modification by parity, obesity, and hormone replacement therapy (HRT) use was investigated.

Results

We identified 5,382 endometrial cancer cases and 72,127 controls. Endometrial cancer was not associated with use of low-dose aspirin (OR 0.97, 95 % CI 0.89–1.05) or non-aspirin NSAIDs (OR 0.96, 95 % CI 0.91–1.02) compared with nonuse. The ORs did not vary with increasing duration or intensity of NSAID use or with type of endometrial cancer. Interaction analyses showed reduced endometrial cancer risk associated with low-dose aspirin use among nulliparous women (OR 0.82, 95 % CI 0.70–0.95) and with non-aspirin NSAID use among women having used HRT (OR 0.90, 95 % CI 0.82–0.99).

Conclusions

We found no association between use of NSAIDs and endometrial cancer risk overall, although there were some indications of risk reductions associated with low-dose aspirin use among nulliparous women and with non-aspirin NSAID use among women having used HRT.

Available only for authorised users

Sorosky JI (2012) Endometrial cancer. Obstet Gynecol 120:383–397PubMedCrossRef

Akhmedkhanov A, Zeleniuch-Jacquotte A, Toniolo P (2001) Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann N Y Acad Sci 943:296–315PubMedCrossRef

Siiteri PK (1978) Steroid hormones and endometrial cancer. Cancer Res 38:4360–4366PubMed

Modugno F, Ness RB, Chen C, Weiss NS (2005) Inflammation and endometrial cancer: a hypothesis. Cancer Epidemiol Biomarkers Prev 14:2840–2847PubMedCrossRef

Wallace AE, Gibson DA, Saunders PT, Jabbour HN (2010) Inflammatory events in endometrial adenocarcinoma. J Endocrinol 206:141–157PubMedCrossRef

Neill AS, Nagle CM, Protani MM, Obermair A, Spurdle AB, Webb PM (2013) Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: a case-control study, systematic review and meta-analysis. Int J Cancer 132:1146–1155PubMedCrossRef

Ulrich CM, Bigler J, Potter JD (2006) Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 6:130–140PubMedCrossRef

Thun MJ, Jacobs EJ, Patrono C (2012) The role of aspirin in cancer prevention. Nat Rev Clin Oncol 9:259–267PubMedCrossRef

Ohno S, Ohno Y, Suzuki N et al (2005) Multiple roles of cyclooxygenase-2 in endometrial cancer. Anticancer Res 25:3679–3687PubMed

10.

Kilic G, Gurates B, Garon J et al (2005) Expression of cyclooxygenase-2 in endometrial adenocarcinoma. Eur J Gynaecol Oncol 26:271–274PubMed

11.

Gao J, Niwa K, Sun W et al (2004) Non-steroidal anti-inflammatory drugs inhibit cellular proliferation and upregulate cyclooxygenase-2 protein expression in endometrial cancer cells. Cancer Sci 95:901–907PubMedCrossRef

12.

Ozalp SS, Eren CY, Bostancioglu RB, Koparal AT (2012) Induction of apoptosis and inhibition of cell proliferation by the cyclooxgenase enzyme blocker nimesulide in the Ishikawa endometrial cancer cell line. Eur J Obstet Gynecol Reprod Biol 164:79–84PubMedCrossRef

13.

Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH (2003) A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 88:684–688PubMedCentralPubMedCrossRef

14.

Sorensen HT, Friis S, Norgard B et al (2003) Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 88:1687–1692PubMedCentralPubMedCrossRef

15.

Danforth KN, Gierach GL, Brinton LA et al (2009) Nonsteroidal anti-inflammatory drug use and endometrial cancer risk in the NIH-AARP Diet and Health Study. Cancer Prev Res 2:466–472CrossRef

16.

Prizment AE, Folsom AR, Anderson KE (2010) Nonsteroidal anti-inflammatory drugs and risk for ovarian and endometrial cancers in the Iowa Women’s Health Study. Cancer Epidemiol Biomarkers Prev 19:435–442PubMedCentralPubMedCrossRef

17.

Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5:138–146PubMedCrossRef

18.

Brasky TM, Moysich KB, Cohn DE, White E (2013) Non-steroidal anti-inflammatory drugs and endometrial cancer risk in the VITamins And Lifestyle (VITAL) cohort. Gynecol Oncol 128:113–119PubMedCentralPubMedCrossRef

19.

Phipps AI, Anderson GL, Cochrane BB et al (2012) Migraine history, nonsteroidal anti-inflammatory drug use, and risk of postmenopausal endometrial cancer. Horm Cancer 3:240–248PubMedCentralPubMedCrossRef

20.

Setiawan VW, Matsuno RK, Lurie G et al (2012) Use of nonsteroidal anti-inflammatory drugs and risk of ovarian and endometrial cancer: the Multiethnic Cohort. Cancer Epidemiol Biomarkers Prev 21:1441–1449PubMedCentralPubMedCrossRef

21.

Blenstrup LT, Knudsen LB (2011) Danish registers on aspects of reproduction. Scand J Public Health 39:79–82PubMedCrossRef

22.

Gjerstorff ML (2011) The Danish Cancer Registry. Scand J Public Health 39:42–45PubMedCrossRef

23.

Jensen VM, Rasmussen AW (2011) Danish education registers. Scand J Public Health 39:91–94PubMedCrossRef

24.

Kildemoes HW, Sorensen HT, Hallas J (2011) The Danish National Prescription Registry. Scand J Public Health 39:38–41PubMedCrossRef

25.

Lynge E, Sandegaard JL, Rebolj M (2011) The Danish National Patient Register. Scand J Public Health 39:30–33PubMedCrossRef

26.

Pedersen CB (2011) The Danish Civil Registration System. Scand J Public Health 39:22–25PubMedCrossRef

27.

Rothman K, Greenland S, Lash TL, Rothman K, Greenland S, Lash TL (2008) Case-control studies. Modern epidemiology, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, pp 111–127

28.

Schmidt M, Hallas J, Friis S (2014) Potential of prescription registries to capture individual-level use of aspirin and other nonsteroidal anti-inflammatory drugs in Denmark: trends in utilization 1999–2012. Clin Epidemiol 6:155–168PubMedCentralPubMedCrossRef

29.

ATC Classification Index with DDDs. World Health Organization Collaborating Centre for Drug Statistics Methodology.http://www.whocc.no/atc_ddd_index/. Accessed 16 Oct 2014

30.

Ray WA (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158:915–920PubMedCrossRef

31.

R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.http://www.R-project.org/. Accessed 2 Nov 2014

32.

Brasky TM, Liu J, White E et al (2014) Non-steroidal anti-inflammatory drugs and cancer risk in women: results from the Women’s Health Initiative. Int J Cancer 135:1869–1883PubMedCrossRef

33.

Fortuny J, Sima C, Bayuga S et al (2009) Risk of endometrial cancer in relation to medical conditions and medication use. Cancer Epidemiol Biomarkers Prev 18:1448–1456PubMedCentralPubMedCrossRef

34.

Bodelon C, Doherty JA, Chen C, Rossing MA, Weiss NS (2009) Use of nonsteroidal antiinflammatory drugs and risk of endometrial cancer. Am J Epidemiol 170:1512–1517PubMedCentralPubMedCrossRef

35.

Viswanathan AN, Feskanich D, Schernhammer ES, Hankinson SE (2008) Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer. Cancer Res 68:2507–2513PubMedCentralPubMedCrossRef

36.

Moysich KB, Baker JA, Rodabaugh KJ, Villella JA (2005) Regular analgesic use and risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev 14:2923–2928PubMedCrossRef

37.

Bosetti C, Bravi F, Talamini R, Montella M, Negri E, La VC (2010) Aspirin and risk of endometrial cancer: a case-control study from Italy. Eur J Cancer Prev 19:401–403PubMedCrossRef

38.

Cook NR, Lee IM, Zhang SM (2013) Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 159:77–85PubMedCentralPubMedCrossRef

39.

Cook NR, Lee IM, Gaziano JM et al (2005) Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA 294:47–55PubMedCrossRef

40.

Cuzick J, Thorat MA, Bosetti C et al (2014) Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol. doi:10.1093/annonc/mdu225 PubMedCentral

41.

Rothwell PM, Price JF, Fowkes FG (2012) Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379:1602–1612PubMedCrossRef

42.

Purdie DM, Green AC (2001) Epidemiology of endometrial cancer. Best Pract Res Clin Obstet Gynaecol 15:341–354PubMedCrossRef

43.

Harvey AE, Lashinger LM, Hursting SD (2011) The growing challenge of obesity and cancer: an inflammatory issue. Ann N Y Acad Sci 1229:45–52PubMedCrossRef

44.

Yood MU, Campbell UB, Rothman KJ et al (2007) Using prescription claims data for drugs available over-the-counter (OTC). Pharmacoepidemiol Drug Saf 16:961–968PubMedCrossRef

Title: Use of nonsteroidal anti-inflammatory drugs and risk of endometrial cancer: a nationwide case–control study
Authors: Nanna Brøns
Louise Baandrup
Christian Dehlendorff
Susanne K. Kjaer
Publication date: 01-07-2015
Publisher: Springer International Publishing
Published in: Cancer Causes & Control / Issue 7/2015
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-015-0578-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2015

Association between plasma adiponectin levels and colorectal cancer risk in women

Even anti-tobacco studies must be held to basic scientific standards. A response to: Smoking intensity and intent to continue smoking among menthol and non-menthol adolescent smokers in Canada

Sleep duration and cancer risk in women

Chronic diseases, medical history and familial cancer, and risk of leukemia and non-Hodgkin’s lymphoma in an adult population: a case–control study

Association between Helicobacter pylori and pancreatic cancer risk: a meta-analysis

Proceedings of the second international molecular pathological epidemiology (MPE) meeting

Keynote webinar | Spotlight on antibody–drug conjugates in cancer